WEGO Corporate and Strategy Overview
Platform-based development
new business initiatives
Digital clinical care
products
Trusted by nearly 50 top-tier
•
tertiary hospitals
•
.
•
•
Helps the nursing department to
enhance standardization and
uniformity level of patient care
services, reducing workload of
medical staff, lowering personnel
costs and enhancing job welfare
Error-free drug administration so
far, preventing the occurrence of
adverse events
With the pilot period of fast
accumulation of customer base,
the installation base is expected to
experience explosive growth by
2023
Generate synergies to boost the
sales of the clinical consumable
products
•
•
Life science information
and support solutions
Leveraged the expertise of the
sales lead who has MNC
experiences, to build a high-
performing sales team
The product portfolio consists of
the monitoring equipment, infusion
pumps, ventilators, and digital
management systems
Achieved 2,000 installations
across various clinical departments
in the first year of the team,
including anesthesia, ICU,
emergency, respiratory and
rehabilitation
Suzhou R&D center has recruited a
state-of-the-art R&D team, with first
product expected to be available
for commercialization by 2024,
bringing in also synergies with
consumables sales
.
Urology
Stents: leveraging the latest
international metal stent technology,
WEGO has set up China sales
office, and has initiated effort to
locally develop the product, which
is set to commercialized in 2
years
Medical energy-based equipment:
targeting on the innovative
solutions including thulium lasers
and pulsed thulium lasers.
Currently WEGO has entered an
initial phase, with plan to explore
the full potential of thulium laser
technology in respiratory, digestive,
head and neck surgery and
medical aesthetics areas
Actively engaging in dialogues with
MNCs to explore partnership
opportunities
.
•
•
Endocrinology
Developed a team in 2022
The product portfolio includes
glucose meters, glucose test strips,
and insulin syringes, etc.
Currently in process to introduce
an overseas CGM product with
superior technology compared to
the competitors, expected to be
launched in 2024
To create a in-and-ex-hospital
chronic disease management
system, for real time
communication between physicians
and patients, to ensure continuous
care on disease progress. Patients
are able to obtain health data in
real time, to achieve an integrated
information management system
WEGO威高
8View entire presentation